5 resultater
FIELD OF THE INVENTION
The present invention is related to medical uses of nanoparticles composed of poly(.gamma.-glutamic acid)-poly(lactide) block copolymers and their uptake by HepG2 cells.
BACKGROUND OF THE INVENTION
Chemotherapy for cancers is usually limited by the toxicity of drugs to normal
FIELD OF THE INVENTION
The present invention is related to nanoparticles composed of poly(.gamma.-glutamic acid)-poly(lactide) block copolymers as a targeting drug delivery system, more particularly, the invention is related to nanoparticles loaded with bioactive agents and targeting ligand toward
TECHNICAL FIELD
This invention relates to improved methods of purification for a polysaccharide.
BACKGROUND
CM101, a GBS toxin, is a pathogenic molecule isolated from group B .beta.-hemolytic Streptococcus (GBS) bacteria. Newborn infants may become infected with GBS, a condition known as GBS
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a National Phase application under 35 U.S.C. .sctn. 371 of International Application No. PCT/CN2015/087717, filed Aug. 21, 2015, which claims the priority benefit of International Patent Application Serial No. PCT/CN2014/085027, filed Aug.
FIELD OF THE INVENTION
The present invention is related to nanoparticles composed of poly(.gamma.-glutamic acid)-poly(lactide) block copolymers as a target drug delivery system, more particularly, the invention is related to nanoparticles loaded with bioactive agents and their uptake by HepG2